3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Primary Myelofibrosis
13
Myeloproliferative Disorders
10
Polycythemia Vera
9
Leukemia, Myeloid, Acute
9
Myelodysplastic Syndromes
6
Graft vs Host Disease
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia
5
Thrombocythemia, Essential
4
Hematologic Neoplasms
4
Breast Neoplasms
4
Myelodysplastic-Myeloproliferative Diseases
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Monocytic, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
Tamoxifen
10
Specimen Handling
5
Chemotherapy, Adjuvant
5
Radiotherapy
3
Mastectomy, Segmental
3
Anastrozole
3
Simvastatin
2
telapristone acetate
1
ruxolitinib
1
exemestane
1
abemaciclib
1
Vinorelbine
1
Trastuzumab
1
Telemedicine
1
Tablets
1
Surgical Procedures, Operative
1
Sugars
1
Starch
1
Soybean Proteins
1
Radiation Dose Hypofractionation
1
Radiation
1
Protons
1
Proton Therapy
1
Probiotics
1
Pharmacogenomic Testing
1
Omacor
1
Neoadjuvant Therapy
1
Naltrexone
1
Mastectomy, Subcutaneous
1
Lovastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Carcinoma In Situ
×
ruxolitinib
×
Clear all
NCT02928978
2026-04-13
TBCRC042
Baylor Breast Care Center
Phase 2
Completed
84 enrolled